SG11202101712XA - Kits and methods for treating cancers - Google Patents
Kits and methods for treating cancersInfo
- Publication number
- SG11202101712XA SG11202101712XA SG11202101712XA SG11202101712XA SG11202101712XA SG 11202101712X A SG11202101712X A SG 11202101712XA SG 11202101712X A SG11202101712X A SG 11202101712XA SG 11202101712X A SG11202101712X A SG 11202101712XA SG 11202101712X A SG11202101712X A SG 11202101712XA
- Authority
- SG
- Singapore
- Prior art keywords
- kits
- methods
- treating cancers
- cancers
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862731500P | 2018-09-14 | 2018-09-14 | |
PCT/US2019/050843 WO2020056156A1 (en) | 2018-09-14 | 2019-09-12 | Kits and methods for treating cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101712XA true SG11202101712XA (en) | 2021-04-29 |
Family
ID=69776732
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101712XA SG11202101712XA (en) | 2018-09-14 | 2019-09-12 | Kits and methods for treating cancers |
SG11202102006YA SG11202102006YA (en) | 2018-09-14 | 2019-09-12 | Crystalline forms of a quinazole compound and its hydrochloride salts |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102006YA SG11202102006YA (en) | 2018-09-14 | 2019-09-12 | Crystalline forms of a quinazole compound and its hydrochloride salts |
Country Status (16)
Country | Link |
---|---|
US (2) | US20220040180A1 (en) |
EP (2) | EP3849964A4 (en) |
JP (2) | JP2022500416A (en) |
KR (2) | KR20210061371A (en) |
CN (2) | CN112770758A (en) |
AR (2) | AR116669A1 (en) |
AU (2) | AU2019337640A1 (en) |
BR (2) | BR112021004546A2 (en) |
CA (2) | CA3110369A1 (en) |
IL (2) | IL281167A (en) |
MX (2) | MX2021002876A (en) |
PH (2) | PH12021550432A1 (en) |
SG (2) | SG11202101712XA (en) |
TW (2) | TW202027750A (en) |
UY (2) | UY38375A (en) |
WO (2) | WO2020056156A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020056156A1 (en) | 2018-09-14 | 2020-03-19 | Spectrum Pharmaceuticals, Inc. | Kits and methods for treating cancers |
CN114642728A (en) * | 2021-06-02 | 2022-06-21 | 德琪(浙江)医药科技有限公司 | Pharmaceutical application of mTOR inhibitor and pharmaceutical composition thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1596869B1 (en) * | 2003-01-21 | 2014-06-04 | New Form Pharmaceuticals Inc. | Novel cocrystallization |
KR100735639B1 (en) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | Quinazoline derivatives inhibiting the growth of cancer cell and preparation thereof |
EP1856095B1 (en) | 2005-02-26 | 2011-08-24 | AstraZeneca AB | Quinazoline derivatives as tyrosine kinase inhibitors |
BRPI0712720A2 (en) * | 2006-05-31 | 2012-11-20 | Abbott Lab | thiazide compounds as cannabinoid receptor ligands and uses thereof |
WO2008012105A1 (en) * | 2006-07-28 | 2008-01-31 | Synthon B.V. | Crystalline erlotinib |
EP2170844B1 (en) | 2007-02-21 | 2016-05-04 | Natco Pharma Limited | Novel polymorphs of erlotinib hydrochloride and method of preparation |
TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
KR101217526B1 (en) * | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof |
KR101317809B1 (en) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant |
KR101272613B1 (en) * | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxy quinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one hydrochloride and intermediates used therein |
UA115686C2 (en) | 2013-03-06 | 2017-12-11 | Астразенека Аб | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
WO2015154725A1 (en) * | 2014-04-11 | 2015-10-15 | 四川海思科制药有限公司 | Quinazoline derivative and preparation method and use in medicine thereof |
US10308658B2 (en) | 2015-10-19 | 2019-06-04 | Sunshine Lake Pharma Co., Ltd. | Salt of EGFR inhibitor, crystalline form and uses thereof |
CA3040348A1 (en) * | 2016-10-19 | 2018-04-26 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating cancer |
MX2019005834A (en) * | 2016-11-17 | 2019-10-14 | Univ Texas | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations. |
WO2020056156A1 (en) | 2018-09-14 | 2020-03-19 | Spectrum Pharmaceuticals, Inc. | Kits and methods for treating cancers |
-
2019
- 2019-09-12 WO PCT/US2019/050843 patent/WO2020056156A1/en unknown
- 2019-09-12 BR BR112021004546-5A patent/BR112021004546A2/en unknown
- 2019-09-12 CN CN201980060160.6A patent/CN112770758A/en active Pending
- 2019-09-12 US US17/275,290 patent/US20220040180A1/en not_active Abandoned
- 2019-09-12 MX MX2021002876A patent/MX2021002876A/en unknown
- 2019-09-12 BR BR112021004527-9A patent/BR112021004527A2/en not_active Application Discontinuation
- 2019-09-12 KR KR1020217010772A patent/KR20210061371A/en unknown
- 2019-09-12 WO PCT/IB2019/057720 patent/WO2020053816A1/en unknown
- 2019-09-12 CA CA3110369A patent/CA3110369A1/en active Pending
- 2019-09-12 SG SG11202101712XA patent/SG11202101712XA/en unknown
- 2019-09-12 EP EP19859287.5A patent/EP3849964A4/en active Pending
- 2019-09-12 EP EP19860538.8A patent/EP3849557A4/en not_active Withdrawn
- 2019-09-12 US US17/275,382 patent/US11883402B2/en active Active
- 2019-09-12 KR KR1020217010957A patent/KR20210046818A/en unknown
- 2019-09-12 CN CN201980060170.XA patent/CN112823153A/en active Pending
- 2019-09-12 JP JP2021513941A patent/JP2022500416A/en active Pending
- 2019-09-12 AU AU2019337640A patent/AU2019337640A1/en not_active Abandoned
- 2019-09-12 CA CA3111062A patent/CA3111062A1/en active Pending
- 2019-09-12 SG SG11202102006YA patent/SG11202102006YA/en unknown
- 2019-09-12 JP JP2021514419A patent/JP2022500456A/en active Pending
- 2019-09-12 AU AU2019340598A patent/AU2019340598A1/en active Pending
- 2019-09-12 MX MX2021002875A patent/MX2021002875A/en unknown
- 2019-09-16 UY UY0001038375A patent/UY38375A/en not_active Application Discontinuation
- 2019-09-16 UY UY0001038374A patent/UY38374A/en unknown
- 2019-09-16 TW TW108133290A patent/TW202027750A/en unknown
- 2019-09-16 AR ARP190102610A patent/AR116669A1/en unknown
- 2019-09-16 AR ARP190102611A patent/AR116406A1/en unknown
- 2019-09-16 TW TW108133291A patent/TW202023562A/en unknown
-
2021
- 2021-03-01 IL IL281167A patent/IL281167A/en unknown
- 2021-03-01 PH PH12021550432A patent/PH12021550432A1/en unknown
- 2021-03-01 IL IL281168A patent/IL281168A/en unknown
- 2021-03-03 PH PH12021550456A patent/PH12021550456A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202006627B (en) | Methods and compositions for treating cancer | |
IL272470A (en) | Methods and materials for assessing and treating cancer | |
IL269150A (en) | Compositions and methods for treating cancer | |
IL263224A (en) | Methods and compositions for treating cancers | |
HK1252937A1 (en) | Methods and kits for treating depression | |
ZA201906236B (en) | Kits and methods for treating hair | |
IL274837A (en) | Methods and compositions for treating cancers | |
EP3883580A4 (en) | Methods of treating cancers | |
IL269157A (en) | Compositions and methods for treating cancer | |
EP3801563A4 (en) | Materials and methods for treating cancer | |
SG11202012435UA (en) | Compositions and methods for treating cancer | |
IL288086A (en) | Methods and materials for treating cancer | |
EP3703669A4 (en) | Methods of treating cancers | |
IL282478A (en) | Materials and methods for treating cancer | |
EP3589659A4 (en) | Compounds and methods for treating cancer | |
IL287907A (en) | Methods for treating cancer | |
IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
SG11202010793UA (en) | Methods of treating cancer | |
EP3494230A4 (en) | Methods for diagnosing and treating esophageal cancer | |
SG11202010528XA (en) | Combinations for treating cancer | |
EP3429613A4 (en) | Compositions and methods for treating cancers | |
EP3697767A4 (en) | Compounds and methods for treating cancer | |
IL277981A (en) | Methods of treating cancer | |
IL281167A (en) | Kits and methods for treating cancers | |
IL281600A (en) | Methods of treating cancer |